Irbesartan

drugbox
width=200


IUPAC_name = 2-butyl-
3- ["p"-("o"-1"H"-tetrazol-5-ylphenyl)benzyl] -
1,3-diazaspiro [4.4] non-1-en-4-one
CAS_number = 138402-11-6
ATC_prefix = C09
ATC_suffix = CA04
PubChem = 3749
DrugBank = APRD00413
C=25 | H=28 | N=6 | O=1
molecular_weight = 428.53
smiles = CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)c1ccccc1c1n [nH] nn1
bioavailability = 60–80%
metabolism = Hepatic (CYP2C9)
elimination_half-life = 11–15 hours
excretion = Renal 20%, faecal 65%
licence_EU = Aprovel
licence_US = Irbesartan
pregnancy_category = D (Au)
legal_status = S4 (Au), POM (UK), ℞-only (U.S.)
routes_of_administration = Oral

Irbesartan (INN) (pronEng|ɜrbəˈsɑrtən) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Clinical use

Indications

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,cite journal | author=Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. | title=Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | journal=N Engl J Med | year=2001 | volume=345 | issue=12 | pages=851–60 | pmid=11565517 | doi=10.1056/NEJMoa011303] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3]

Combination with diuretic

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including Irda, CoIrda, CoAprovel, Karvezide, Avalide and Avapro HCT.

References

ee also

*Angiotensin II receptor antagonist